Systemic lupus erythematosus

Lancet

Volumn 357, Issue 9261, 2001, Pages 1027-1032

  Ruiz Irastorza, Guillermo ^a,b   Khamashta, Munther A ^a   Castellino, Gabriella ^a   Hughes, Graham R V ^a  

^a ST THOMAS HOSPITAL   (United Kingdom)

^b HOSPITAL DE MENDARO   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTIMALARIAL AGENT; BROMOCRIPTINE; CHLOROQUINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; HORMONE; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PRASTERONE; THALIDOMIDE; WARFARIN;

ACNE; AMENORRHEA; ANTIPHOSPHOLIPID SYNDROME; CAUSE OF DEATH; CLINICAL FEATURE; CLINICAL TRIAL; CONFERENCE PAPER; DISEASE CLASSIFICATION; DISEASE SEVERITY; HIGH RISK PREGNANCY; HIRSUTISM; HORMONAL THERAPY; HUMAN; INCIDENCE; MENSTRUAL IRREGULARITY; NEPHRITIS; NEUROPSYCHIATRY; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROGNOSIS; PUBLICATION; STEM CELL TRANSPLANTATION; SURVIVAL RATE; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOSIS;

EID: 0035978096     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(00)04239-2     Document Type: Conference Paper

References (91)

1. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus
2. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus: Comment on the letter by Hochberg
3. The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes
4. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome
5. Validation of the Sapporo criteria for antiphospholipid syndrome
6. Trends in the incidence and mortality of systemic lupus erythematosus, 1950-1992
7. Epidemiology and estimated population burden of selected autoimmune diseases in the United States
8. Special report: Adjusted lupus prevalence. Results of a marketing study by the Lupus Foundation of America
9. Prevalence of self-reported physician-diagnosed systemic lupus erythematosus in the USA
10. Systemic lupus erythematosus survival in Hungary: Results from a single centre
11. Mortality studies in systemic lupus erythematosus: Results from a single center, III - Improved survival in SLE
12. Mortality and causes of death of 513 Danish patients with systemic lupus erythematosus
13. Evolving spectrum of mortality and morbidity in SLE
14. Morbidity and mortality in systemic lupus erythematosus during a 5-year period: A multicenter prospective study of 1,000 patients. European Working Party on Systemic Lupus Erythematosus
15. Mortality studies in systemic lupus erythematosus: Results from a single center, II - Predictor variables for mortality
16. Systemic lupus erythematosus in Malaysia: A study of 539 patients and comparison of prevalence and disease expression in different racial and gender groups
17. Long term follow-up of patients with systemic lupus erythematosus
18. Systemic lupus erythematosus in Indian patients: Prognosis, survival and life expectancy
19. Systemic lupus erythematosus and lupus syndromes in Senegal: A retrospective study of 30 patients seen over 10 years
20. Causes of death in Korean patients with systemic lupus erythematosus: A single center retrospective study
21. Mortality studies in systemic lupus erythematosus: Results from a single center, I - Causes of death
22. Premature morbidity from cardiovasculr and cerebrovascular diseases in women with systemic lupus erythematosus
23. Age specific incidence rates of myocardial infarction and angina in women with SLE: Comparison with the Framingham study
24. The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus
25. Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis: A randomized, controlled trial
26. Randomized controlled trial of pulse/synchronization cyclophosphamide/apheresis for proliferative lupus nephritis
27. Intravenous immunoglobulin compared with cyclophosphamide for proliferative lupus nephritis
28. Recombinant human DNase (rhDNase) in patients with lupus nephritis
29. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis
30. Controlled trial with chloroquine diphosphate in systemic lupus erythematosus
31. Double-blind, randomized, placebo-controlled clinical trial of methotrexate in systemic lupus erythematosus
32. Dehydroepiandrosterone in systemic lupus erythematosus: Results of a double-blind, placebo-controlled, randomized clinical trial
33. A double-blind, placebo-controlled, clinical trial of dehydroepiandrosterone in severe systemic lupus erythematosus
34. Bromocriptine in systemic lupus erythematosus: A double-blind randomized, placebo-controlled study
35. A randomized study of the effect of withdrawing hydroxychloroquine sulphate in systemic lupus erythematosus
36. Methotrexate in patients with moderate systemic lupus erythematosus (exclusion of renal and central nervous system disease)
37. Cyclosporin A in the treatment of systemic lupus erythematosus: Results of an open clinical study
38. Long-term treatment of systemic lupus erythematosus with cyclosporin A
39. Thalidomide in the treatment of cutaneous manifestations of lupus erythematosus: Experience in sixteen consecutive patients
40. Experience with low-dose thalidomide in chronic discoid lupus erythematosus
41. Clinical and immunologic parameters during thalidomide treatment of lupus erythematosus
42. Long-term thalidomide use in refractory cutaneous lesions of systemic lupus erythematosus
43. Thalidomide in the treatment of cutaneous lupus refractory to conventional therapy
44. Thalidomide induces amenorrhea in patients with lupus disease
45. High dose intravenous immunoglobulins in systemic lupus erythematosus: Clinical and serological results of a pilot study
46. Intravenous immunoglobulin therapy is not able to efficiently control cutaneous manifestations in patients with lupus erythematosus
47. A study of 20 SLE patients with intravenous immunoglobulin: Clinical and serologic response
48. Successful mycophenolate mofetil treatment of glomerular disease
49. Mycophenolate mofetil for lupus nephritis refractory to intravenous cyclophosphamide
50. Mycophenolate mofetil therapy in lupus nephritis: Clinical observations
51. Mycophenolate mofetil for the treatment of systemic lupus erythematosus: An open pilot trial
52. Mycophenolate mofetil treatment of systemic lupus erythematosus
53. Stem cells transplantation: A cure for autoimmune disease
54. Autologous marrow stem cell transplantation for severe systemic lupus erythematosus of long duration
55. Hematopoietic stem-cell transplantation for systemic lupus erythematosus
56. Control of severe systemic lupus erythematosus after high-dose immunosuppressive therapy and transplantation of CD34+ purified and autologous stem cells from peripheral blood
57. Successful treatment of refractory systemic lupus erythematosus (SLE) by autologous stem cell transplantation (ASCT) with in vivo immunoablation and ex vivo depletion of mononuclear cells
58. Treatment of severe systemic lupus erythematosus with high-dose chemotherapy and haemopoietic stem-cell transplantation: A phase I study
59. Immunoablative high-dose cyclophosphamide without stem-cell rescue for refractory, severe autoimmune disease
60. High-dose immunoablative cyclophosphamide in SLE
61. A pilot study of 2-chloro-2′-deoxyadenosine in the treatment of systemic lupus erythematosus-associated glomerulonephritis
62. Cladribine in the treatment of systemic lupus erythematosus nephritis
63. A pilot study of low-dose fludarabine in membranous nephropathy refractory to therapy
64. Successful treatment of lupus with fludarabine
65. Treatment of severe and difficult cases of systemic lupus erythematosus with tacrolimus: A report of three cases
66. Improvement of renal function with a selective thromboxane A2 synthetase inhibitor, DP-1904, in lupus nephritis
67. Reduction in circulating dsDNA antibody titer after administration of LJP 394
68. Results of a phase I, single-dose, dose-escalating trial of a humanized anti-CD40L monoclonal antibody (IDEC-131) in patients with systemic lupus erythematosus
69. Responsiveness of peripheral blood B cells to recombinant CD40 ligand in patients with systemic lupus erythematosus
70. Clinical and biologic effects of anti-interleukin-10 monoclonal antibody administration in systemic lupus erythematosus
71. The management of thrombosis in the antiphospholipid-antibody syndrome
72. Antiphospholipid thrombosis: Clinical course after the first thrombotic event in 70 patients
73. Guidelines on oral anticoagulation: Third edn.
74. Antiphospholipid antibodies and venous thromboembolism
75. Anticardiolipin antibodies predict early recurrence in thromboembolism and death among patients with venous thromboembolism following anticoagulant therapy
76. Antiphospholipid antibodies and thrombosis
77. Bleeding and clotting in patients with the antiphospholipid syndrome treated with high-intensity oral anticoagulation
78. Increased rate of lupus flare during pregnancy and the puerperium: A prospective study of 78 pregnancies
79. Systemic lupus erythematosus and antiphospholipid syndrome during pregnancy: Maternal and fetal complications and their management
80. Hopkins Lupus Pregnancy Center: 1987 to 1996
81. Clinical predictors of fetal outcome in systemic lupus erythematosus
82. Antiphospholipid syndrome in pregnancy: Obstetric concerns and treatment
83. A study of sixty pregnancies in patients with the antiphospholipid syndrome
84. Obstetric outcome in antiphospholipid syndrome
85. Pregnancy complications in women with recurrent miscarriage associated with antiphospholipid antibodies treated with low dose aspirin and heparin
86. Antiphospholipid antibody-associated recurrent pregnancy loss: Treatment with heparin and low-dose aspirin is superior to low-dose aspirin alone
87. Randomised controlled trial of aspirin and aspirin plus heparin in pregnant womenwith recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies)
88. Does aspirin have a role in improving pregnancy outcome for women with the antiphospholipid syndrome? A randomized controlled trial
89. A multicenter, placebo-controlled pilot study of intravenous immune globulin treatment of antiphospholipid syndrome during pregnancy
90. Safety of low-molecular-weight heparin in pregnancy: A systematic review
91. Thromboprophylaxis in antiphospholipid syndrome pregnancies with previous cerebral arterial thrombotic events: Is warfarin preferable?